Navigation Links
Encorium Group, Inc. Completes $1.6 Million Private Placement of Common Stock and Executes Warrant Exchange Agreement; Ends Discussions to Sell Encorium OY
Date:10/19/2009

positioned to win future contracts in the vaccine and oncology fields. As a result, the Company believes stockholder value will be maximized by moving ahead independently, while continuing to focus on clinical vaccine development.

Dr. Kai Lindevall, executive chairman stated, "We are very pleased that we were able to close this financing to shore up our balance sheet and provide the Company with additional working capital. Our experience and capabilities in the vaccine field coupled with the recent new awards in this area demonstrate the long term potential we have to grow into a leading vaccine franchise with expertise in pre-clinical support, regulatory consultancy and strategic trial planning. We believe these developments will position us to move ahead independently and are in the best interest of all stockholders."

Of the 35,000,000 authorized capital stock of the Company, 26,325,383 shares of common stock will be issued and outstanding immediately following the closing.

The shares of common stock issued in connection with the above transactions have not been registered under the Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration under the Securities Act and applicable state securities laws or an applicable exemption from those registration requirements. The Exchange Shares will be immediately freely transferable pursuant to Rule 144 of the Act since the Investors are not affiliates of the Company and since the Investors will be deemed to have held the Exchange Shares for greater than 6 months pursuant to (d)(3)(ii) of Rule 144. For additional information on the transactions described below, please see our Current Report on Form 8-K filed with the SEC on October 19, 2009, which is available on the SEC website at www.sec.gov

Quarterly Results and Conference Call

Financial results for the third q
'/>"/>

SOURCE Encorium Group, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Encorium Group, Inc. Announces New Business Awards of $8.7 Million, Including Swine Flu (Influenza A H1N1 virus) Vaccine Trial Win;
2. Encorium Announces Receipt of Letters from Nasdaq Regarding its Second Quarter 2009 Form 10-Q Filing
3. Encorium Reports Second Quarter 2009 Financial Results
4. Encorium Group Completes Sale of its U.S. Business to Pierrel Research USA; Announces Management Changes
5. Encorium Group Updates Expected Timeframe with Respect to the Sale of its U.S. Business
6. Professor Hanna Nohynek Joins Encorium as Head Consultant of its Clinical Vaccine Research Team
7. Encorium Named as Finalist for the Second Annual Vaccine Industry Excellence Award
8. Encorium Group Signs Approximately $2.0 Million of New Business Contracts
9. Encorium Group Signs $3.1 Million of New Business Contracts Including an Extension of a Current U.S. Oncology Clinical Trial with a Major Pharmaceutical Company
10. Encorium Announces Receipt of Letter from Nasdaq Regarding its Third Quarter 2008 Form 10-Q Filing
11. Encorium Reports Third Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... memory device for computing may have just taken an ... New York led by chemist Stephen O,Brien have discovered ... properties. , Combining both properties is very exciting scientifically ... for the devices that might ultimately be designed, in ... a single material, however, has proved difficult until now. ...
(Date:9/18/2014)... 18, 2014 September 24 marks ASEA's ... ASEA is the manufacturer of the world's first and ... product, RENU28. , The Mexico City event features ... Botero, and ASEA Field Leader Shawn Catmull from Draper, ... in Atomic/Medical Physics from the University of Utah and ...
(Date:9/17/2014)... , Sept. 17, 2014 A ... accelerated partial breast irradiation (APBI) via interstitial brachytherapy ... with positive lymph nodes could be suitable to ... Oncology (ASTRO) guidelines place these patients in the ... at the 2014 ASTRO meeting, Beaumont Health System,s ...
(Date:9/17/2014)... N.C. , Sept. 17, 2014  The In ... topics that will be featured at the conference, which ... Center on December 3 and 4, 2014. Researchers, students, ... invited to hear the following: KEYNOTE ... San Diego Skaggs School of Pharmacy ...
Breaking Biology Technology:Oxides discovered by CCNY team could advance memory devices 2Announcing the ASEA Mexico Grand Opening Tour Beginning September 18th 2Partial Breast Irradiation With Interstitial Brachytherapy Appears Appropriate For Women Previously Considered Unsuitable 2Partial Breast Irradiation With Interstitial Brachytherapy Appears Appropriate For Women Previously Considered Unsuitable 3Partial Breast Irradiation With Interstitial Brachytherapy Appears Appropriate For Women Previously Considered Unsuitable 4In Silico Drug Discovery Conference Announces Speakers and Topics 2In Silico Drug Discovery Conference Announces Speakers and Topics 3In Silico Drug Discovery Conference Announces Speakers and Topics 4In Silico Drug Discovery Conference Announces Speakers and Topics 5In Silico Drug Discovery Conference Announces Speakers and Topics 6In Silico Drug Discovery Conference Announces Speakers and Topics 7
... are used in a wide variety of applications ... and aerospace applications. Thermal analysis is routinely used ... growing trend to use nanostructured materials has made ... an atomic force microscope-based technique called nanoscale thermal ...
... laboratory has found a way to turn common carbon ... with properties expected to prove useful in electronic, optical ... scientist Pulickel Ajayan, in collaboration with colleagues in China, ... one-step chemical process that is markedly simpler than established ...
... cell therapy manufacturing division, Progenitor Cell Therapy ("PCT"), ... NBS ) ("NeoStem" or the "Company"), announced today ... and regulatory services related to the development of ... injectable suspension of microencapsulated insulin-producing, pancreatic islet cells ...
Cached Biology Technology:Magnetic actuation enables nanoscale thermal analysis 2Graphene quantum dots: The next big small thing 2Graphene quantum dots: The next big small thing 3Islet Sciences, Inc. Selects NeoStem's Manufacturing Subsidiary Progenitor Cell Therapy for Product Manufacturing 2Islet Sciences, Inc. Selects NeoStem's Manufacturing Subsidiary Progenitor Cell Therapy for Product Manufacturing 3Islet Sciences, Inc. Selects NeoStem's Manufacturing Subsidiary Progenitor Cell Therapy for Product Manufacturing 4
(Date:9/18/2014)... 18, 2014 Elsevier, a world-leading provider of ... and the Australasian Research Management Society (ARMS), recognized ... at the 5th Scopus Young Researcher of the ... today at the National Convention Centre and in ... attended by guests representing Australia,s and New Zealand,s ...
(Date:9/18/2014)... of camouflage: you don,t just blend in, the background ... uncommon as you might think. Kathryn Feller, from the ... larval life stages of many marine species are transparent. ... most creatures cannot make transparent. Feller explains that the ... eye unit with an opaque pigment to prevent light ...
(Date:9/17/2014)... affordable health care to reproductive technologies, the justice ... ability of people to identify key issues, articulate ... and find the most defensible ways forward. But ... these societal conversations?, The Hastings Center and the ... have teamed up to publish a series of ...
Breaking Biology News(10 mins):Elsevier and Australasian Research Management Society award scientists at Scopus ceremony 2Transparent larvae hide opaque eyes behind reflections 2Why bioethics literacy matters 2Why bioethics literacy matters 3
... Jizhou Song, a professor in the University of Miami ... Rogers, at the University of Illinois and Professor Yonggang ... for stretchable electronics that can be wrapped around complex ... The new mechanical design strategy is based on semiconductor ...
... Researchers from Joslin Diabetes Center, Boston, and ActiveSite ... have demonstrated that a specific inhibitor of the ... may provide a new therapeutic approach for treatment ... of diabetes. The study, which was partly funded ...
... that human male fertility is impacted by long-term exposure ... in the male reproductive tract, further suggesting a functional ... test to clarify mechanisms. Now, in a paper on ... the phenotype of mice genetically lacking FAAH, fatty acid ...
Cached Biology News:University of Miami engineer designs stretchable electronics with a twist 2Researchers describe protease inhibitor that may aid in diabetic retinopathy treatment 2Researchers describe protease inhibitor that may aid in diabetic retinopathy treatment 3February 2009 highlights from Biology of Reproduction 2
Smac/DIABLO (mouse) (CT) rabbit polyclonal antibody...
... to ADAMTS16 ( Abpromise for ... Antigen: Synthetic peptide based on ... Note: the amino acid sequence is ... 170690 SWISS ...
... Immunogen: KLH-conjugated, synthetic ... in which [ Ac K] corresponds to ... Accession Number: NM_003493 ... ~17kDa Quality Assurance: ...
synaptotagmin XIV-like [Source:RefSeq_peptide;Acc:NP_114120] Antigen: Recombinant Protein Epitope Signature Tag (PrEST)....
Biology Products: